Artelo Biosciences gets UK regulatory guidance for anxiety drug trial Aug 1, 2025 07:45AM
Artelo Biosciences Receives Favorable UK MHRA Guidance for a Phase 1 Trial of ART12.11, the Company’s Proprietary CBD:TMP Cocrystal Being Developed for the Treatment of Anxiety and Depression Aug 1, 2025 07:45AM
Artelo Biosciences Provides Business Update and Reports First Quarter 2025 Financial Results May 13, 2025 08:00AM
Artelo Biosciences to Present Novel Scientific Insights for ART26.12 at the 4th ACE Drug Discovery Summit on April 3, 2025 Mar 31, 2025 08:30AM
Artelo Biosciences Provides Business Update and Reports Fiscal 2024 Year-End Financial Results Mar 3, 2025 08:00AM
View Older Stories

Jan 13, 2025 09:00AM Artelo Biosciences Announces Successful Completion of First Cohort in a Phase 1 Study of ART26.12
Dec 9, 2024 09:15AM Artelo Biosciences (ARTL) Announces Presentation of Phase 1 Data with ART27.13 in Cancer-Related Anorexia
Dec 9, 2024 09:15AM Artelo Biosciences Announces Presentation of Phase 1 Data with ART27.13 in Cancer-Related Anorexia
Nov 18, 2024 08:30AM Artelo Biosciences to Present Key Data on Three Development Programs at the 7th Cannabinoid Drug Development Summit 
Nov 13, 2024 08:30AM Artelo Biosciences Announces Promising New Data on Novel Non-Opioid Treatment Approach for Osteoarthritis Pain at the 13th Annual Musculoskeletal Repair and Regeneration Symposium
Nov 12, 2024 08:00AM Artelo Biosciences Reports Third Quarter 2024 Financial Results and Provides Business Update
Nov 5, 2024 08:30AM Artelo Biosciences Announces Acceptance of ART26.12 into the National Institutes of Health’s “Preclinical Screening Platform for Pain” Program
Oct 9, 2024 09:00AM Artelo Biosciences CEO to Participate in Fireside Chat at the Maxim Group Virtual Healthcare Summit on October 16th
Sep 4, 2024 09:00AM Artelo Biosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Aug 13, 2024 08:00AM Artelo Biosciences Reports Second Quarter 2024 Financial Results and Provides Business Update
Jul 15, 2024 08:31AM Artelo Biosciences (ARTL) Receives FDA Clearance of its IND Application for ART26.12, a Selective Fatty Acid Binding Protein 5 Inhibitor
Jul 15, 2024 08:30AM Artelo Biosciences Receives FDA Clearance of its IND Application for ART26.12, a Selective Fatty Acid Binding Protein 5 Inhibitor
Jul 3, 2024 09:00AM Artelo Biosciences Presents Comparative Data from Key Preclinical Studies on ART12.11 at the 34th Annual International Cannabinoid Research Society Symposium
Jul 1, 2024 09:00AM Artelo Biosciences Presents Preclinical Data on ART26.12 in Breast Cancer-Induced Bone Pain at the 34th Annual International Cannabinoid Research Society Symposium
Jun 4, 2024 08:30AM Artelo Biosciences Presents Important New Data on ART26.12 at the 57th Annual Scientific Meeting of the British Pain Society
May 29, 2024 08:32AM Artelo Biosciences (ARTL) Presents Highly Encouraging Data Towards Developing a Solid Dosage Form of ART12.11 at CT-CANN24
May 29, 2024 08:30AM Artelo Biosciences Presents Highly Encouraging Data Towards Developing a Solid Dosage Form of ART12.11 at CT-CANN24
May 13, 2024 08:00AM Artelo Biosciences Reports First Quarter 2024 Financial Results and Provides Business Update
May 10, 2024 09:00AM Artelo Biosciences to Present at the Pharma Partnering Summit 2024 on May 14th
Apr 23, 2024 08:32AM Artelo Biosciences (ARTL) Reports Publication of Peer-Reviewed Article Highlighting FABP7
Apr 23, 2024 08:30AM Artelo Biosciences Announces Publication of Peer-Reviewed Article Highlighting FABP7 as a Promising Novel Target in Cancer Therapy
Apr 22, 2024 08:30AM Artelo Biosciences CEO to Appear on Benzinga All Access on April 23rd at Approximately 10:50 AM Eastern Time
Mar 25, 2024 08:00AM Artelo Biosciences Reports Fiscal 2023 Year-End Financial Results and Provides Business Update
Mar 12, 2024 09:15AM Artelo Biosciences (ARTL) Picked as a Finalist in Johnson & Johnson’s (JNJ) Innovation Challenge
Mar 12, 2024 09:15AM Artelo Biosciences Selected as a Finalist in Johnson & Johnson’s Innovation Challenge
Feb 15, 2024 09:00AM Artelo Biosciences to Present at the Winter Wrap-Up MicroCap Rodeo Conference on February 20th
Jan 23, 2024 08:32AM Artelo Biosciences (ARTL) Reports Publication of Pre-Clinical Research Demonstrating ART26.12’s Effectiveness
Jan 23, 2024 08:30AM Artelo Biosciences Announces Publication of New Peer-Reviewed Pre-Clinical Research Demonstrating ART26.12’s Effectiveness in Treating and Preventing Oxaliplatin-Induced Peripheral Neuropathy
Jan 8, 2024 08:30AM Artelo Biosciences Announces Selection of Worldwide Clinical Trials as Clinical Research Organization to Support First-in-Human Study of ART26.12
Dec 5, 2023 08:30AM Artelo Biosciences Presents New Preclinical Data on ART12.11 at the 4th Annual Med-Cannabis 2023 Conference in Germany
Nov 30, 2023 09:00AM Artelo Biosciences to Present Important New Preclinical Data on ART12.11 at the 4th Annual Med-Cannabis 2023 Conference in Germany
Nov 13, 2023 08:00AM Artelo Biosciences Reports Third Quarter 2023 Financial Results and Provides Business Update
Nov 9, 2023 09:00AM Artelo Biosciences Announces Publication of New Peer-Reviewed Research Demonstrating Protective Properties of ART27.13 Against Muscle Degeneration Caused by Certain Cancers
Nov 2, 2023 08:30AM Artelo Biosciences to Present Preclinical Data Showcasing Research on ART26.12 and ART12.11 in Anxiety and Depression at Neuroscience 2023
Oct 4, 2023 08:30AM Principal Investigator of Artelo’s CAReS Trial to Participate in Medical Expert Webinar Hosted by H.C. Wainwright to Discuss Current Development Strategies for Cancer-Related Anorexia and Cachexia
Sep 13, 2023 08:30AM Artelo Biosciences to Present at the 13th Congress of the European Pain Federation on September 20th
Sep 7, 2023 08:06AM Artelo Biosciences (ARTL) Completes Positive Pre-IND Meeting with FDA for ART26.12
Sep 7, 2023 08:00AM Artelo Biosciences Completes Positive Pre-IND Meeting with FDA for ART26.12
Sep 6, 2023 09:00AM Artelo Biosciences to Present at the 6th Cannabinoid-Derived Drug Development Summit on September 12th
Sep 5, 2023 09:00AM Artelo Biosciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference on September 13th
Aug 10, 2023 08:00AM Artelo Biosciences Reports Second Quarter 2023 Financial Results and Provides Business Update
Jul 19, 2023 09:00AM Artelo Biosciences to Present New Mechanism of Action Data on ART26.12 at the Gordon Research Conference on July 20, 2023
Jul 10, 2023 08:30AM Artelo Biosciences CEO to Participate in the Benzinga All Access Event on July 11
Jun 28, 2023 08:30AM Artelo Biosciences Announces Sponsorship of The William A. Devane Early Career Investigator Award at the 33rd Annual International Cannabinoid Research Society Symposium
Jun 27, 2023 08:37AM Artelo Biosciences (ARTL) Announces Important New Data on ART26.12 Demonstrating Positive Effects in Multiple Models of Neuropathic Pain at the 33rd Annual International Cannabinoid Research Society S
Jun 27, 2023 08:30AM Artelo Biosciences Announces Important New Data on ART26.12 Demonstrating Positive Effects in Multiple Models of Neuropathic Pain at the 33rd Annual International Cannabinoid Research Society Symposiu
Jun 26, 2023 08:33AM Artelo Biosciences (ARTL) Reports Superior Preclinical Pharmaceutical Properties and Efficacy of ART12.11 Compared to Cannabidiol
Jun 26, 2023 08:30AM Artelo Biosciences Reports Superior Preclinical Pharmaceutical Properties and Efficacy of ART12.11 Compared to Cannabidiol (CBD) at the 33rd Annual International Cannabinoid Research Society Symposiu
Jun 7, 2023 08:30AM Artelo Biosciences Selected for Oral Presentation to Report Positive Research Findings on ART12.11 at the 33rd Annual International Cannabinoid Research Society Symposium
May 11, 2023 08:00AM Artelo Biosciences Reports First Quarter 2023 Financial Results and Provides Business Update
View Older Stories